$0.81
9.19% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
US63909J1088
Symbol
NAUT
Sector
Industry

Nautilus Biotechnology Stock price

$0.89
-0.35 28.06% 1M
-1.84 67.32% 6M
-0.79 46.90% YTD
-1.82 67.08% 1Y
-3.68 80.48% 3Y
-9.55 91.46% 5Y
-9.55 91.46% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.06 7.47%
ISIN
US63909J1088
Symbol
NAUT
Sector
Industry

Key metrics

Market capitalization $112.54m
Enterprise Value $13.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-81.48m
Free Cash Flow (TTM) Free Cash Flow $-61.27m
Cash position $129.89m
EPS (TTM) EPS $-0.56
P/E forward negative
Short interest 0.83%
Show more

Is Nautilus Biotechnology a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Nautilus Biotechnology Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Nautilus Biotechnology forecast:

2x Buy
40%
2x Hold
40%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Nautilus Biotechnology forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from Nautilus Biotechnology

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 11 11
96% 96%
-
-11 -11
96% 96%
-
- Selling and Administrative Expenses 12 12
37% 37%
-
- Research and Development Expense 47 47
3% 3%
-
-70 -70
0% 0%
-
- Depreciation and Amortization 11 11
96% 96%
-
EBIT (Operating Income) EBIT -81 -81
7% 7%
-
Net Profit -71 -71
11% 11%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nautilus Biotechnology directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nautilus Biotechnology Stock News

Negative
Seeking Alpha
about one month ago
Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, whic...
Neutral
Seeking Alpha
about one month ago
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brenn...
Neutral
GlobeNewsWire
5 months ago
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging
More Nautilus Biotechnology News

Company Profile

Nautilus Biotechnology, Inc. develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Sujal Patel
Employees 155
Founded 2016
Website www.nautilus.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today